Marrow aplasia during high dose mebendazole treatment.
A patient with chronic liver disease was treated with large doses of mebendazole for a hepatic hydatid cyst. Eighteen days after beginning treatment he developed marrow aplasia which reverted to normal after the drug was stopped. This is the marrow aplasia which reverted to normal after the drug was stopped. This is the sixth patient described as developing marrow aplasia when treated with large doses of mebendazole. We suggest that the aplasia is related to the dose of the drug, and that the patient's chronic liver disease was an important factor in its genesis. Patients treated with large doses of mebendazole should have their blood counts monitored during treatment.
D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced*; D001853:Bone Marrow / Q000187:drug effects; D004444:Echinococcosis, Hepatic / Q000188:drug therapy; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008463:Mebendazole / Q000009:adverse effects* / Q000627:therapeutic use; D009503:Neutropenia / Q000139:chemically induced*
D008463:Mebendazole